Core Viewpoint - China Biologic Products (01177.HK) has announced that its self-developed innovative drug TQB2102, a HER2 dual-target antibody-drug conjugate (ADC), is currently undergoing a Phase III clinical trial to evaluate its efficacy and safety compared to chemotherapy in HER2 low-expressing recurrent/metastatic breast cancer [1][2]. Group 1 - TQB2102 is a next-generation HER2 dual epitope bispecific antibody-drug conjugate developed by the company, which optimizes the balance between efficacy and safety through three core technological innovations [2]. - The first innovation is the dual epitope targeting design, which employs an asymmetric structural design for the antibody end, significantly enhancing selectivity for tumor cells and drug internalization efficiency, thereby increasing anti-tumor activity [2]. - The second innovation involves a cleavable linker that efficiently releases toxins and possesses a "bystander effect," which helps eliminate surrounding heterogeneous tumor cells, thus expanding the killing range [2]. - The third innovation is the optimized drug-antibody ratio (DAR), which is stably controlled between 5.8 and 6.0, combined with a topoisomerase I (Topo I) inhibitor toxin, enhancing efficacy while reducing side effects [2]. - The combination of these core technologies breaks through the limitations of traditional HER2 monoclonal antibodies and single-target ADCs, demonstrating significant potential for TQB2102 in treating HER2 low-expressing tumors [2].

Core Viewpoint - The company is advancing its self-developed innovative drug TQB2102, a HER2 dual-targeted antibody-drug conjugate (ADC), through a Phase III clinical trial to evaluate its efficacy and safety in patients with HER2 low-expressing recurrent or metastatic breast cancer [1][2] Group 1: Clinical Trial and Drug Development - TQB2102 is undergoing a randomized, open-label, parallel-controlled Phase III clinical trial (TQB2102-III-01) to compare its effectiveness against chemotherapy in HER2 low-expressing breast cancer [1] - The drug incorporates three core technological innovations: dual-target design, cleavable linker, and optimized drug-antibody ratio (DAR), enhancing its antitumor activity and safety profile [1] Group 2: Clinical Results - At the 2025 ASCO annual meeting, the company reported promising results from a Phase Ib clinical study of TQB2102 in HER2 low-expressing advanced breast cancer, showing an overall objective response rate (ORR) of 53.4% among previously treated patients [2] - Notably, in the 7.5 mg/kg group, the ORR reached 58.3%, and 44.4% of patients who had previously progressed on ADC treatment achieved a response after TQB2102 therapy [2] - The safety profile indicated that grade 3 or higher treatment-related adverse events (TRAEs) included neutropenia (23.3%), leukopenia (20.6%), anemia (8.2%), and hypokalemia (6.9%), with overall tolerability being good [2] Group 3: Market Positioning - The company has established a comprehensive portfolio in breast cancer treatment, covering various molecular subtypes including HER2+, HER2 low-expressing, HR+/HER2-, and triple-negative breast cancer, aiming to provide new treatment options across all stages of disease management [2]

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) has seen a stock increase of over 6%, currently trading at HKD 11.57, with a transaction volume of HKD 12.83 million. The rise is attributed to the FDA granting breakthrough therapy designation for JSKN003, aimed at treating specific types of advanced ovarian cancer in patients previously treated with bevacizumab [1]. Group 1 - Corning Jereh Pharmaceutical announced that its product JSKN003 has received breakthrough therapy designation from the FDA for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer in adults who have previously been treated with bevacizumab [1]. - JSKN003 is a self-developed HER2 dual antibody ADC, with ongoing Phase III clinical trials in China for multiple indications. The efficacy and safety of JSKN003 have shown superior characteristics compared to Enhertu in the platinum-resistant ovarian cancer population [1]. - The company expects to complete data readout for JSKN003 by 2027 and plans to submit a New Drug Application (NDA) to the CDE for 2L HER2-positive breast cancer in 2026. Additionally, a Phase III clinical trial for HER2-positive metastatic colorectal cancer is set to start in October 2025, with projected sales for JSKN003 estimated at 0.05 billion, 0.57 billion, and 1.08 billion for the years 2027, 2028, and 2029 respectively [1].

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) has seen a stock increase of over 6% following the announcement that its drug JSKN003 has received breakthrough therapy designation from the FDA for treating advanced or metastatic ovarian cancer, primary peritoneal cancer, or fallopian tube cancer in patients previously treated with bevacizumab [1] Group 1 - JSKN003 is a self-developed HER2 dual antibody ADC by the company, currently undergoing orderly Phase III clinical trials in China for multiple indications [1] - The efficacy and safety of JSKN003 in platinum-resistant ovarian cancer have shown characteristics superior to Enhertu, with data readout expected in 2027 and a New Drug Application (NDA) submission to the CDE for 2L HER2-positive breast cancer anticipated in 2026 [1] - The company plans to initiate Phase III clinical trials for HER2-positive metastatic colorectal cancer in China by October 2025, with projected sales for JSKN003 expected to be 0.05 billion, 0.57 billion, and 1.08 billion in 2027, 2028, and 2029 respectively [1]

Core Insights - China Biologic Products (01177.HK) announced preliminary data from the first human Phase I clinical study of TQB2102, a HER2 bispecific antibody-drug conjugate (ADC), presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting [1] Efficacy Summary - The trial included 181 patients with advanced solid tumors who had no standard treatment options as of October 1, 2024, including both HER2-positive and HER2 low-expressing patients [1] - In terms of efficacy, the objective response rate (ORR) for HER2-positive breast cancer in the 6mg/kg and above dose group was 51.3%, while for HER2 low-expressing breast cancer, the ORR was 51.5% [1] - The ORR for HER2 high-expressing (HER2 IHC 3+) colorectal cancer was 34.8%, and for HER2-positive gastric or gastroesophageal junction adenocarcinoma, the ORR was 70% [1] - Among the subgroup of HER2-positive breast cancer patients with brain metastases, the ORR was 70%, with one case achieving complete resolution of intracranial lesions [1] - 31% of breast cancer patients who were resistant to T-DM1/DS-8201 still responded to TQB2102 treatment [1] Safety Summary - In terms of safety, the main ≥3 grade adverse events (AE) in the overall population included neutropenia (21.7%), decreased white blood cell count (10.6%), anemia (8.9%), and decreased platelet count (6.1%) [2] - Notably, only one case (0.55%) of grade 2 interstitial lung disease (ILD) was reported, which is significantly lower than the incidence seen with similar drug DS-8201 (greater than 10%) [2] - TQB2102 has shown significant clinical benefits across multiple advanced malignancies while maintaining a low incidence of ILD, achieving a balance between efficacy and safety [2] - Currently, TQB2102 is undergoing Phase III clinical trials and has the potential to reshape the treatment landscape for HER2 ADCs [2]